Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics ( (AU:TYP) ) has issued an update.
Tryptamine Therapeutics Limited announced the resignation of Mark Davies as a director, effective May 12, 2025. This change in leadership is accompanied by a disclosure of Davies’ interests in the company’s securities, including various unlisted director options and ordinary fully paid shares. The departure of a director may impact the company’s strategic direction and stakeholder confidence, particularly given Davies’ significant holdings and involvement with the company.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited operates in the pharmaceutical industry, focusing on the development of innovative therapeutic solutions. The company is involved in the research and production of treatments that aim to address various health conditions, with a particular emphasis on advancing mental health therapies.
Average Trading Volume: 1,751,616
Technical Sentiment Signal: Buy
Current Market Cap: A$50.36M
See more data about TYP stock on TipRanks’ Stock Analysis page.